CD274 and glioblastoma: It was recently documented that both the number of PD-1+ tumor-infiltrating lymphocytes and PD-L1 expression are significantly increased in GBM, providing a rationale for the use of immune checkpoint blockade to interrupt the PD-1/PD-L1 axis as a potential therapy for GBM (67–69).